Introduction to the Rat Model of Cardiomyopathy

Rat models of cardiomyopathy are predominantly established through pharmacological induction, surgical modeling, or genetic modification, thereby mimicking clinically common forms such as dilated and hypertrophic cardiomyopathy. These animal models exhibit hallmark pathological features, including myocardial hypertrophy, ventricular chamber enlargement, disorganized myocardial fibers, and interstitial fibrosis, accompanied by phenotypes such as impaired cardiac function and abnormal cardiac enzyme levels. They can recapitulate the disease progression and functional impairment characteristic of cardiomyopathy, making them well suited for investigating pathogenic mechanisms, screening therapeutic agents, and evaluating drug efficacy.

Service Advantages of the Aniphe BioLab Rat Model Platform for Cardiomyopathy

This platform boasts a comprehensive system for establishing and evaluating rat models of cardiomyopathy, with mature technologies and end-to-end services that can meet the needs of diverse basic research and drug development projects.

	A full range of models is available. It is possible to establish various cardiomyopathy models, including hypertrophic and dilated types, with well‑established modeling protocols and phenotypes that closely mirror clinical presentations.
	Model establishment is stable and reliable. The procedure is minimally invasive, causes minimal trauma to the animals, achieves a high modeling success rate, exhibits small intergroup differences, and demonstrates excellent reproducibility.
	Quality Control System Standards End-to-end standardized management, multi‑metric validation models, complete and traceable data, and compliance with regulatory requirements.
	Comprehensive testing capabilities It is equipped with a range of assays, including cardiac function, pathology, and molecular analyses, covering various stages of experimentation.
	Flexible and efficient service Supports customized experimental protocols, offers end-to-end closed-loop delivery, and features a short project cycle.

Modeling cycle	4–10 weeks
Laboratory animals	SPF-grade rats
Positive drug	There is no specific positive drug; depending on the modeling method, drugs such as sacubitril/valsartan, mavacoxib, and sotalol may be selected.
Application areas	It is primarily used to investigate the pathological mechanisms underlying cardiac hypertrophy, myocardial fibrosis, and cardiac functional decline, as well as to screen for anti‑cardiomyopathic agents and evaluate the efficacy and safety of drugs that modulate ventricular remodeling. It can also be employed for validating drug targets and developing bioactive compounds.

Construction of Animal Models of Cardiomyopathy

01 Dilated cardiomyopathy (DCM): primarily induced by intraperitoneal injection of doxorubicin to elicit myocardial mitochondrial toxicity; alternatively, subcutaneous multiple-site injections of porcine cardiac myosin emulsified with complete Freund’s adjuvant can trigger the development of autoimmune myocarditis that progresses to a chronic phase.

02 Hypertrophic cardiomyopathy (HCM): The most commonly used preclinical model is transverse aortic constriction (TAC), in which the aortic arch is partially ligated using sutures and needle‑based pledgets to induce pressure overload. Mechanistic studies, on the other hand, directly employ transgenic mice carrying spontaneous mutations or knockouts of the α‑MHC or MyBPC3 genes to establish the disease phenotype.

03 Restrictive cardiomyopathy (RCM): The core approach involves generating transgenic mice carrying a cardiac troponin I gene mutation, which directly induces diastolic dysfunction through alterations in myocardial microstructure, or alternatively, inducing diffuse interstitial fibrosis over the long term by administering high-dose isoproterenol (ISO) in combination with aldosterone and a high-salt diet.

04 Arrhythmogenic cardiomyopathy (ACM): The standard preclinical model is a cardiac‑specific knockout mouse harboring desmosomal gene mutations; following model induction, high‑intensity exercise regimens, such as daily forced swimming, are employed to accelerate the lipodystrophic replacement of right ventricular cardiomyocytes.